新辅助奥希替尼治疗I-IIIA期EGFR突变NSCLC：II期多中心研究

文章预览

SCI 1 August 2024 Neoadjuvant Osimertinib for the Treatment of Stage I-IIIAEpidermal Growth Factor Receptor–Mutated Non–Small CellLung Cancer: A Phase II Multicenter Study  (JCO, IF: 42.1) Blakely CM, Urisman A, Gubens MA, et al: Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: A Phase II Multicenter Study. J Clin Oncol JCO2400071, 2024 Purpose 目的 To assess the safety and efficacy of the third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor osimertinib as neoadjuvant therapy in patients with surgically resectable stage I-IIIA EGFR-mutated non-small cell lung cancer (NSCLC). 评价第三代表皮生长因子受体(EGFR)酪氨酸激酶抑制剂 osimertinib 对可手术切除的 I-IIIA 期 EGFR 突变型非小细胞肺癌(NSCLC)患者的新辅助治疗的安全性和有效性。 Patients and methods 患者和方法 This was a multi-institutional phase II trial of neoadjuv ………………………………